FY2025 EPS Estimates for BrainsWay Cut by HC Wainwright

BrainsWay Ltd. (NASDAQ:BWAY) – Stock analysts at HC Wainwright cut their FY2025 EPS estimates for shares of BrainsWay in a research note issued to investors on Wednesday, March 12th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.18 for the year, down from their prior forecast of $0.32. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.08 per share.

BrainsWay Stock Down 0.3 %

Shares of NASDAQ BWAY opened at $10.18 on Monday. The firm’s 50-day moving average price is $10.28 and its 200-day moving average price is $9.66. The company has a market cap of $191.66 million, a PE ratio of 101.81 and a beta of 1.29. BrainsWay has a 52-week low of $4.61 and a 52-week high of $11.79.

Hedge Funds Weigh In On BrainsWay

Several institutional investors have recently made changes to their positions in BWAY. Lazard Asset Management LLC bought a new position in shares of BrainsWay in the 4th quarter worth approximately $44,000. JPMorgan Chase & Co. lifted its stake in shares of BrainsWay by 316.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock worth $136,000 after purchasing an additional 11,221 shares during the period. Sei Investments Co. bought a new position in shares of BrainsWay in the 4th quarter worth approximately $149,000. Cubist Systematic Strategies LLC lifted its stake in shares of BrainsWay by 14.6% in the 4th quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock worth $181,000 after purchasing an additional 2,446 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of BrainsWay by 10.8% in the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock worth $207,000 after purchasing an additional 2,144 shares during the period. Institutional investors own 30.11% of the company’s stock.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.